<乌鸦传媒>New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCT Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk Dec 14, 2022
<乌鸦传媒>'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLL Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease Dec 14, 2022
<乌鸦传媒>Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALL Phase III study showed 58% reduction in the risk of death versus chemo alone Dec 13, 2022
<乌鸦传媒>AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCT Similar outcomes if patients went directly to transplant or received intensive salvage first Dec 11, 2022
<乌鸦传媒>Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
<乌鸦传媒>Year in Review: Acute Lymphoblastic Leukemia New ways to use CAR T-cell therapy and treatment de-intensification strategies Dec 05, 2022
<乌鸦传媒>New IDH1 Inhibitor Wins FDA Approval for Acute Myeloid Leukemia Olutasidenib led to a 35% response rate in a study of adults with previously treated AML Dec 02, 2022
<乌鸦传媒>Transplant With Orca-T Reduced GVHD in Hematologic Malignancies Risk of relapse was also lower in the group who received the cell therapy Oct 03, 2022
<乌鸦传媒>Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML? Strategy applied in OPTIC trial may mitigate adverse events without sacrificing benefit Sep 29, 2022
<乌鸦传媒>Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDS About a third of patients, including those with TP53 mutations, achieved complete remission Sep 29, 2022
<乌鸦传媒>'Unparalleled Times' in Hematology, but Workforce Issues Persist "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
<乌鸦传媒>What's on Tap at the Society of Hematologic Oncology's 10th Annual Meeting Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
<乌鸦传媒>CAR-T Therapy Effective in Youngest Kids With ALL Analysis shows safety and outcomes equivalent to those reported in older children Sep 08, 2022
<乌鸦传媒>Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomes Overall response rates were 67% with decitabine, 48% with azacitidine Aug 22, 2022
<乌鸦传媒>Two More Patients With HIV Surviving Without Antiretrovirals Functional cures now seen in 5 patients Jul 29, 2022
<乌鸦传媒>'Rogue' Online Pharmacies Are Dispensing Cancer Drugs Shady sites with little oversight are selling imatinib for much less than U.S. retail price Jul 29, 2022
<乌鸦传媒>Zanubrutinib Wins in First-Line CLL for Older Patients The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial Jul 08, 2022
<乌鸦传媒>FDA Warns of Increased Mortality Risk With Duvelisib Drug approved for adults with CLL/SLL Jul 01, 2022
<乌鸦传媒>FDA Panel Backs Gene Tx for Degenerative Brain Disorder in Kids Advisers unanimously recommend approval for pediatric ALD patients without HLA-matched donors Jun 10, 2022
<乌鸦传媒>FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisib Worse overall survival observed despite improvements in progression-free survival Jun 01, 2022
<乌鸦传媒>Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Too "Viable" option for patients eligible for umbilical cord blood transplantation, investigator says Apr 27, 2022
<乌鸦传媒>Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDS 1-year relapse-free survival rate of 60% with maintenance therapy after transplant Apr 25, 2022
<乌鸦传媒>9/11 Responders More Likely to Carry Genetic Mutations Tied to Cancer Clonal hematopoiesis seen in 10% of firefighters, medical personnel on the scene after WTC attack Mar 07, 2022
<乌鸦传媒>Third Person 'Cured' of HIV via Transplant U.S. woman with leukemia gets cord blood resistant to HIV Feb 16, 2022
<乌鸦传媒>Women More Likely to Experience Severe Toxicity of Cancer Treatments Increased risk was particularly pronounced among those receiving immunotherapy Feb 14, 2022
<乌鸦传媒>Illusionist Criss Angel's Son's Acute Leukemia Famed magician speaks about the long battle Feb 09, 2022
<乌鸦传媒>Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemia OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy Dec 17, 2021
<乌鸦传媒>Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLL Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease Dec 16, 2021
<乌鸦传媒>Can Dasatinib Dose Be Halved in Low-Risk CML? Lower dose associated with improved tolerability, similar responses in propensity score analysis Dec 14, 2021
<乌鸦传媒>Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALL One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
<乌鸦传媒>Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Rates Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
<乌鸦传媒>Upfront IDH1 Inhibitor Triples Survival in Older AML Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy Dec 11, 2021
<乌鸦传媒>Next-Gen MRD Testing Predicts Acute Leukemia Relapse After CAR-T Nearly all patients with detectable disease relapsed or progressed to transplant, other therapies Dec 01, 2021
<乌鸦传媒>Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patients Zanubrutinib plus obinutuzumab and venetoclax was also well tolerated Nov 29, 2021
<乌鸦传媒>Pegylated Interferon Wins FDA Approval for Polycythemia Vera Majority of patients attained complete hematologic response with ropeginterferon alfa-2b Nov 15, 2021
<乌鸦传媒>A Gentler Standard for Acute Promyelocytic Leukemia in Kids ATRA/arsenic trioxide without maintenance therapy resulted in 99-100% survival at 2 years Nov 11, 2021
<乌鸦传媒>FDA Approves STAMP Inhibitor for Chronic Myeloid Leukemia Patients treated with two or more TKIs and those with T315I mutation gain new option Nov 01, 2021
<乌鸦传媒>What Happens When All the Great Doctors Are Gone? In commemoration of the late Elihu (Eli) Estey, MD Oct 13, 2021
<乌鸦传媒>Life Expectancy Still Lower for Blood or Marrow Transplant Recipients Although late mortality has decreased over the past 40 years Sep 09, 2021
<乌鸦传媒>Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemia Complete responses in 18 of 20 patients with relapsed/refractory T-cell ALL Aug 04, 2021
